Fulcrum Therapeutics, Inc.

NASDAQ:FULC

4.55 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q4
Revenue 08000.8710.7590.880.2950.6851.1831.8822.5925.0584.9354.3814.7894.2251.84820.7500000000
Cost of Revenue 017.2610.4790.5080.50.60.5660.5910.625.0190.5360.62117.07717.37816.33418.86814.86112.77514.4829.8413.49610.8634.6290000
Gross Profit 062.739-0.4790.3630.2590.28-0.2710.0940.583-23.1372.0564.437-12.142-12.997-11.545-14.643-13.013-10.775-13.732-9.84-13.496-10.86-34.6290000
Gross Profit Ratio 00.78400.4170.3410.318-0.9190.1370.493-12.2940.7930.877-2.46-2.967-2.411-3.466-7.042-5.388-18.30900000000
Reseach & Development Expenses 14.63917.26119.29418.99918.23817.84916.71518.56615.36625.01917.83118.91217.07717.37816.33416.14515.6412.77514.48212.08713.49610.8634.6296.866.9635.7885.573
General & Administrative Expenses 8.42410.24710.0619.8649.96110.32311.5210.139.70711.09810.7599.7058.6286.6855.4985.8675.3125.1495.0644.4033.512.6342.5982.3912.1252.0611.737
Selling & Marketing Expenses 000-0.50800000000000000000000000
SG&A 8.42410.24710.0619.3569.96110.32311.5210.139.70711.09810.7599.7058.6286.6855.4985.8675.3125.1495.0644.4033.512.6342.5982.3912.1252.0611.737
Other Expenses 2.06302.9643.2363.4233.5093.1611.8380.6170.1650.070.0750.0540.0340.0440.0670.1420.2390.3440.0070.0070.0080.0070.0070.0070.0080.37
Operating Expenses 25.12627.50829.35528.35528.19928.17228.23528.69625.07336.11728.5928.61725.70524.06321.83222.01220.95217.92419.54616.4917.00613.49437.2279.2519.0887.8497.31
Operating Income -25.12652.492-29.834-27.992-27.44-27.292-27.94-27.973-24.355-34.235-25.998-23.559-20.77-19.682-17.043-17.787-19.104-15.924-18.796-16.49-17.006-13.494-37.227-9.251-9.088-7.849-7.31
Operating Income Ratio 00.6560-32.138-36.153-31.014-94.712-40.836-20.587-18.191-10.03-4.658-4.209-4.493-3.559-4.21-10.338-7.962-25.06100000000
Total Other Income Expenses Net 3.432.9172.9643.2363.4233.5093.1611.8380.6170.1650.070.0750.0540.0340.0440.0670.1420.2390.3440.3670.4640.3250.3840.3920.1450.0030.37
Income Before Tax -21.69655.409-26.87-24.756-24.017-23.783-24.779-26.135-23.738-34.07-25.928-23.484-20.716-19.648-16.999-17.72-18.962-15.685-18.452-16.123-16.542-13.169-36.843-8.859-8.943-7.846-6.94
Income Before Tax Ratio 00.6930-28.423-31.643-27.026-83.997-38.153-20.066-18.103-10.003-4.643-4.198-4.485-3.55-4.194-10.261-7.843-24.60300000000
Income Tax Expense 000.4353.1610.4090.525-3.161-2.5050.313-0.024-0.07-0.6210.019-0.0280-0.733000-0.879-0.457-0.317-0.377-0.385-0.1380.0050
Net Income -21.69655.409-26.87-24.756-24.017-23.783-21.618-23.63-24.051-34.07-25.858-23.484-20.716-19.648-16.999-17.72-18.962-15.685-18.452-16.123-16.542-13.169-36.843-8.859-8.943-7.846-6.94
Net Income Ratio 00.6930-28.423-31.643-27.026-73.281-34.496-20.331-18.103-9.976-4.643-4.198-4.485-3.55-4.194-10.261-7.843-24.60300000000
EPS -0.350.89-0.43-0.4-0.39-0.38-0.36-0.45-0.52-0.83-0.64-0.58-0.57-0.6-0.54-0.64-0.7-0.66-0.81-0.71-0.93-0.56-1.58-0.52-0.53-0.46-0.41
EPS Diluted -0.350.87-0.43-0.4-0.39-0.38-0.36-0.45-0.52-0.83-0.64-0.58-0.57-0.6-0.54-0.64-0.7-0.66-0.81-0.71-0.93-0.56-1.58-0.52-0.53-0.46-0.41
EBITDA -22.69455.809-29.355-27.484-26.909-26.725-27.374-27.42-23.279-33.559-25.462-22.938-20.151-19.01-16.44-17.054-18.55-15.371-18.257-15.971-16.49-12.98-36.723-8.742-8.629-7.646-7.136
EBITDA Ratio 00.6560-31.555-35.453-30.369-94.712-40.947-19.285-17.832-9.823-4.658-4.083-4.339-3.433-4.21-10.038-7.686-24.34300000000